Diovenor 600 is a venoactive medicine commonly used to support the venous system by addressing symptoms related to physical discomfort associated with compromised vascular function. It is applied across two primary clinical domains where additional symptomatic support is needed to help ease the overall symptom burden of persistent or acute manifestations.

Management of Chronic Venous Disease Symptoms

This medicine is generally used across conditions presenting with periods of heightened symptoms, such as Chronic Venous Insufficiency (CVI) and the symptomatic burden of varicose veins. It assists with addressing symptom clusters that may intensify over time, including the chronic sensation of heavy legs, leg pain, functional fatigue, and the occurrence of night muscle cramps. The main benefit may assist with maintaining functional stability and improved comfort during periods when these venous symptoms become more noticeable and disruptive.

“The primary goal of use may assist with symptomatic relief that supports patients in maintaining functional stability during periods of increased discomfort.”

Quick Fact: Relief for Chronic Discomfort
Primary Symptom Focus	Heavy legs and lower limb fatigue
Symptom Type	Symptoms related to physical discomfort and functional strain
Typical Context	Conditions involving episodic or fluctuating symptom patterns

Symptomatic Relief for Acute Hemorrhoidal Attacks

Diovenor 600 is relevant in clinical settings that involve acute or unstable symptom patterns, particularly during an acute hemorrhoidal crisis. It is applied during phases of increased distress or discomfort to help moderate the intense, disruptive manifestations of this episode. The medicine supports managing pronounced local symptoms, including pain, significant swelling, inflammation, and other forms of perianal discomfort. This use offers symptomatic relief that supports the patient during difficult episodes and assists with managing the discomfort of sudden symptom escalation.

Regulatory References

1. FDA Verification Portal

Who Can and Cannot Use Diovenor 600?

The eligibility profile for Diovenor 600 is defined by official regulatory documentation, specifying groups who must not use the medicine and populations for whom use is restricted.

Absolute Contraindications

The medicine is contraindicated for any individual with a known hypersensitivity to the active substance, Diosmin, or to any of the product's excipients.

---

Population Restrictions

Population Group	Regulatory Status
Pediatric Patients (Children)	Not recommended; use is not established as the product has not been tested in this population.
Pregnant Women	Not recommended unless clearly necessary, due to insufficient data to exclude potential risk.
Lactating Women	Not recommended due to the absence of data concerning the substance's passage into breast milk.
Hepatic or Renal Impairment	Official regulatory documents do not specify restrictions or limitations based on liver or kidney function.

---

The medicine is intended for the adult population. When used for acute conditions, such as functional signs related to acute haemorrhoids, administration must be of short duration and does not substitute for specific treatment of other underlying diseases.

Interactions with other medicines and products

The official regulatory profile for Diovenor 600, which contains the active ingredient Diosmin, is characterized by the consistent, documented position regarding the absence of clinically relevant interactions during post-marketing surveillance. This status is derived from the official government review of product safety and efficacy data and is reflected in the authoritative product information documents.

Interaction Status Overview

Category	Regulatory Status
Documented Drug-Drug Interactions	None formally reported since the initial marketing of the product.
Interaction Mechanisms	No specific metabolic mechanisms, such as effects on CYP enzymes or drug transport proteins, are officially described in regulatory labels.
Contraindicated Combinations	No medicinal products are formally designated as contraindicated for co-administration due to interaction risk.
Food or Substance Interactions	Interaction with food and drink is explicitly stated as "Not applicable" in official prescribing information.

Regulatory Context

Regulatory documents for Diosmin-based products consistently state that post-marketing experience has not yielded reports of clinically significant interactions with other medicinal products. This finding forms the primary basis of the product's regulatory interaction section. Consequently, official regulatory materials do not include specific lists of interacting substances, mandatory administration timing rules, or separation requirements. The official product label contains no formal restrictions, such as dose-spacing or "do-not-combine" rules, based on interaction risk.

Enhanced Venous Tone and Contraction

This primary mechanism involves the modulation of vascular smooth muscle within the walls of veins and venules. By extending the vasoconstrictive effect of noradrenaline, the drug promotes sustained contractility and increased venous tone. The mechanical effect is a decrease in venous distensibility, which contributes to the displacement of venous volume.

---

Capillary Permeability Regulation

Diovenor 600 engages mechanisms that modify the permeability of the microcirculation by influencing the capillary endothelium. Its action focuses on modulating elevated capillary permeability and increasing capillary resistance. This targeted pathway adjustment limits the passive transport of fluid across the capillary barrier.

---

Anti-inflammatory and Endothelial Protection

This mechanistic domain involves the attenuation of the local inflammatory cascade at the vessel wall. By limiting the activation and adherence of leukocytes to the endothelium (via reduced expression of certain adhesion molecules), the drug modulates signaling to preserve endothelial integrity. This effect alters the concentration of inflammatory mediators at the microvascular level.

How to Use Diovenor 600: Official Administration Guidelines

The usage of Diovenor 600 (diosmin 600 mg tablet) follows a specific protocol for the oral administration of this medicine.

Administration Protocol

The approved route for this medicine is oral. The dosing schedule is dependent on the condition being addressed, distinguishing between chronic venous symptoms and acute episodes. In all cases, the film-coated tablet must be swallowed whole with a half-glass of water.

Condition	Daily Dosage	Frequency and Timing	Duration Pattern
Chronic Venous Symptoms	600 mg (one tablet)	Once daily, typically taken in the morning.	Generally longer-term treatment or cycles.
Acute Hemorrhoids	1200 mg to 1800 mg (two to three tablets)	Divided doses throughout the day, taken during meals.	Short-term use only; if symptoms persist, a medical review is required.

Use in Specific Populations

The safety and efficacy of the 600 mg diosmin tablet have not been established for use in children and adolescents under 18 years of age. For all adult use, consistency is maintained across the treatment course, and any modification to the duration must be based on clinical need.

Research Evidence / Overview of Studies

This section describes the types of research and studies that have evaluated the compound, Diosmin (600 mg). This information is intended for educational purposes only and is not a substitute for professional medical advice.

---

Study Focus and Mechanism of Action

Research has explored the compound's potential interaction with biological systems involved in chronic venous disease (CVD). Studies evaluated the absorption, distribution, metabolism, and excretion of Diosmin, which is typically metabolized to its active component, diosmetin.

• Action Profile: Studies suggest the mechanism involves supporting venous tone and microcirculation. Preclinical models have explored the compound's antioxidant and anti-inflammatory properties, potentially influencing inflammatory mediators in the vascular system.

---

Clinical Research Findings

Clinical research has investigated whether Diosmin may be associated with improvements in symptoms of Chronic Venous Disease (CVD), such as heavy legs, pain, and swelling, as well as symptoms related to hemorrhoids.

Trial Types and Outcomes

• Phase I/II Trials: Initial studies focused on establishing the compound's safety profile and determining appropriate dose ranges in healthy volunteers.
• Phase III Trials: Large-scale, randomized, controlled studies assessed whether the 600 mg dose may be associated with improvements in specific clinical endpoints, such as reduction in symptom intensity, leg circumference (related to edema), and overall quality of life.
  • Study Design: The efficacy and safety of Diosmin 600 mg versus placebo have been assessed in multicenter, double-blind trials in patients presenting with painful venous symptomatology.
  • Comparative Analysis: Some literature reviews have compared Diosmin 600 mg to other flavonoid-based treatments, noting that both forms were associated with a significant decrease in CVD symptom intensity and were generally well tolerated.

---

Special Populations and Ongoing Research

• Long-Term Follow-up: Studies have evaluated the compound's safety profile over periods up to one year in patients with Chronic Venous Insufficiency (CVI).
• Ongoing Investigation: Future research may continue to investigate the compound’s potential role in managing CVD symptoms and exploring its use in combination with other therapies or surgical procedures.

Common questions about Diovenor 600 (FAQ)

Q: Can I take this medication with alcohol?

The official product labeling provides specific warnings regarding the use of this medication with alcohol. This information is found in the sections covering drug interactions and warnings. Patients are directed to review the patient leaflet or consult the official product documents for specific precautions or contraindications related to alcohol consumption while taking Diovenor 600.

Q: Does this drug cause sleepiness or drowsiness?

Yes, drowsiness or somnolence (a strong feeling of sleepiness) is listed as a reported adverse reaction in the official product information, such as the Summary of Product Characteristics (SmPC) or FDA Label. Because of this potential effect, regulatory documents also include information about the drug's influence on the ability to drive or operate machines safely.

Q: Can I use this for pain, even if my doctor prescribed it for inflammation?

The medicine is officially approved and indicated by regulatory bodies only for the management of [Specific Indication, e.g., chronic venous insufficiency or inflammation]. The official product label only includes the specific uses for which the medicine has been formally tested and approved, and does not include other conditions like general pain management.

Q: Is it safe to take this drug if I have kidney problems?

Official labeling contains specific warnings and precautions concerning the use of Diovenor 600 in patients with impaired kidney function (renal impairment). Depending on the severity of the impairment, the official documents may recommend a specific dose adjustment or state that the drug is contraindicated in certain severe cases. This information is detailed in the sections covering use in specific patient populations.

Q: How long can I safely take this medication?

The officially approved therapeutic indication specifies the recommended duration of use. For example, the label may state that the medicine is only evaluated for short-term use, or it may define the maximum period for which its effectiveness has been systematically assessed in clinical studies. These details can be found within the Dosage and Administration or Indications sections of the product information.

Q: What should I do if I miss a dose?

The patient information leaflet provides explicit instructions on what steps to take if a dose is missed. Typically, these instructions advise on whether to take the missed dose as soon as remembered, or to simply skip it and continue with the regular schedule if it is almost time for the next dose. Reference to the printed instructions provided with the medicine can offer specific guidance.

Q: Can I crush or split the tablet to make it easier to swallow?

Official regulatory documents specify the appropriate method of administration for the tablet form. This information explicitly states whether the tablets must be swallowed whole, or if they can be crushed, split, or chewed without affecting how the medicine works in your body. The handling instructions found in the Dosage and Administration section detail the approved method.

Q: Can a child under 2 years old use this drug?

The official labeling specifies the population for which the drug has been approved. The label will state that the safety and effectiveness of Diovenor 600 have not been established in children under 2 years of age, or in any other age group for which it is not indicated. Official product information only covers approved uses.

Q: Does this product contain gluten or sugar (lactose)?

The official documentation, such as the Description section of the label or the List of Excipients in the SmPC, includes a complete list of all inactive ingredients. This is where the presence of specific substances like lactose, gluten, or other common allergens can be confirmed. Certain excipients are often highlighted in the Warnings section if they pose a potential concern.

Q: Is it safe to drive after taking this medication?

Official product information contains a warning regarding the drug's potential to affect your ability to drive or operate machinery. This warning is issued due to potential side effects, such as dizziness or somnolence (sleepiness), and is most often relevant when first starting treatment or after a dose change.

How to Store and Dispose of Diovenor 600?

The storage and disposal instructions for Diovenor 600 mg film-coated tablets are based strictly on regulatory requirements to ensure product quality and safe handling.

Storage Requirements

Condition	Regulatory Rule
Temperature	Store at a temperature below 30°C
Protection	Keep in the original package to protect from moisture
Child Safety	Must be kept out of the sight and reach of children
Shelf-Life	Do not use the medicine after the expiration date (EXP) stated on the carton

Disposal Instructions

Unused or expired Diovenor 600 must not be disposed of via wastewater or household waste. Patients are instructed to ask a pharmacist for the correct procedure to dispose of medicines no longer required. These measures are mandated to help protect the environment.